Lpath’s iSONEP fails in Phase II wet-AMD study

20 May 2015

USA-based Lpath (Nasdaq: LPTN) says that its multicenter, Phase II "Nexus" clinical trial evaluating iSONEP in patients with wet age-related macular degeneration (wet-AMD) did not meet its primary or key secondary endpoints. The company’s shares nose-dived in pre-market trading this morning, falling 73.8% to $0.45.

Wet AMD patients who had not responded adequately to existing anti-vascular endothelial growth factor (VEGF) therapies including Lucentis (ranibizumab), Avastin bevacizumab) and Eylea (aflibercept) did not show any statistically-significant improvement in visual acuity when treated with iSONEP as an adjunctive or monotherapy.

This is the second disappointment for Lpath in the last couple of months, when the company’ announced that its investigational therapy Asonep (sonepcizumab) did not meet the primary endpoint in a Phase IIa trial in renal cell carcinoma (The Pharma Letter March 25).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK